[Pain therapy using anti-nerve growth factor antibodies? : Pain research in a dilemma]

[Article in German]

Affiliations

Editorial

[Article in German]

Hans-Georg Schaible. Schmerz. 2021 Oct.

. 2021 Oct;35(5):301-303.

doi: 10.1007/s00482-021-00574-1. Epub 2021 Sep 20.

¹ Institut für Physiologie I, Universitätsklinikum Jena, Am Teichgraben 8, 07743, Jena, Deutschland. Hans-Georg.Schaible@med.uni-jena.de.

No abstract available

Comment on

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety.
Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, Viktrup L. Schmelz M, et al. Pain. 2019 Oct;160(10):2210-2220. doi: 10.1097/j.pain.0000000000001625. Pain. 2019. PMID: 31145219 Free PMC article. Review.

1. Bannwarth B, Kostine M (2017) Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer? Drugs 77:1377–1387 - DOI
1. Bennett D (2007) NGF, sensitization of nociceptors. In: Schmidt RF, Willis WD (Hrsg) Encyclopedia of Pain, Bd. 2. Springer, Berlin Heidelberg New York Tokyo, S 1338–1342 - DOI
1. Casser H‑R, Schaible H‑G (2015) Muskuloskeletaler Schmerz. Schmerz 29:486–495 - DOI
1. Lane NE, Schnitzer TJ, Birbara CA et al (2010) Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 363:1521–1531 - DOI
1. Miller RE, Block JA, Malfait A‑M (2018) What is new in pain modification in osteoarthritis? Baillieres Clin Rheumatol 57:iv99–iv107